title: Targeted therapies for gynecologic malignancies.
abstract: Despite the enormous promise that targeted therapies hold for patients with gynecologic malignancies, it is far too early to recommend any targeted therapy outside of a clinical trial. There remains considerable work to be done before targeted therapies will have a significant role in this patient population. We have learned that different tumor types express different targets, but that the mere expression of a target does not necessarily correlate with benefit from the use of the targeted agent. No less important is the challenge of determining how these agents should be studied in clinical trials, and what constitutes an active agent. To document efficacy, targeted agents would hopefully produce response (ie, shrinkage of measurable tumor), but as cytostatic agents, the ability to delay tumor growth or slow the development of symptoms would be clinically important. Combining targeted therapies with cytotoxic agents, radiation, or other targeted therapies may be important areas for study, but it is essential to demonstrate the additive or synergistic effect of the targeted therapy to an already established active one. This review covers strategies used to develop targeted agents, reviews available targeted therapies, and suggests potential roles in the treatment of gynecologic cancers.
authors.affiliation: University of Oklahoma- HSC, PO Box 26901, Oklahoma City, OK 73190, USA.
authors.forename: Johnny
authors.initials: J
authors.lastname: Hyde
authors.forename: D Scott
authors.initials: DS
authors.lastname: McMeekin
mesh_terms: D003131:Combined Modality Therapy; D016503:Drug Delivery Systems; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D006801:Humans; D009361:Neoplasm Invasiveness / Q000473:pathology*; D009367:Neoplasm Staging; D011379:Prognosis; D011878:Radiotherapy; D018714:Radiotherapy, Adjuvant; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D066246:ErbB Receptors
references.citation: Lancet. 2004 May 29;363(9423):1802-11
references.pmid: 15172781
references.citation: J Clin Oncol. 2004 Mar 1;22(5):777-84
references.pmid: 14990632
references.citation: Gynecol Oncol. 1997 Aug;66(2):250-4
references.pmid: 9264571
references.citation: Int J Gynecol Pathol. 1997 Jul;16(3):256-62
references.pmid: 9421092
references.citation: Gynecol Oncol. 1996 Aug;62(2):278-81
references.pmid: 8751561
references.citation: Clin Cancer Res. 2000 May;6(5):2053-63
references.pmid: 10815932
references.citation: J Clin Oncol. 2003 Jun 15;21(12):2237-46
references.pmid: 12748244
references.citation: JAMA. 2003 Oct 22;290(16):2149-58
references.pmid: 14570950
references.citation: Am J Clin Oncol. 2003 Oct;26(5):e150-6
references.pmid: 14528090
references.citation: Gynecol Oncol. 2004 Oct;95(1):32-6
references.pmid: 15385107
references.citation: Cancer Res. 2001 Mar 15;61(6):2420-3
references.pmid: 11289108
references.citation: Br J Cancer. 1996 Feb;73(3):301-6
references.pmid: 8562334
references.citation: J Natl Cancer Inst. 1998 Mar 18;90(6):447-54
references.pmid: 9521169
references.citation: Br J Cancer. 2004 Aug 2;91(3):418-24
references.pmid: 15238978
references.citation: J Clin Oncol. 2002 Feb 15;20(4):1147-9
references.pmid: 11844842
references.citation: Cancer Treat Rev. 2003 May;29 Suppl 1:33-9
references.pmid: 12738241
references.citation: J Clin Oncol. 2004 Jun 1;22(11):2184-91
references.pmid: 15169807
references.citation: J Clin Oncol. 2002 Nov 15;20(22):4478-84
references.pmid: 12431972
references.citation: J Reprod Med. 2004 Feb;49(2):71-5
references.pmid: 15018431
references.citation: Ann Pharmacother. 2004 Jul-Aug;38(7-8):1258-64
references.pmid: 15187215
references.citation: J Clin Oncol. 2004 Mar 1;22(5):785-94
references.pmid: 14990633
references.citation: Clin Cancer Res. 1999 Mar;5(3):577-86
references.pmid: 10100709
references.citation: Oncogene. 2003 Sep 29;22(42):6570-8
references.pmid: 14528282
references.citation: Semin Oncol. 2003 Feb;30(1 Suppl 1):21-9
references.pmid: 12644981
references.citation: Ann Oncol. 1998 Oct;9(10):1047-52
references.pmid: 9834816
references.citation: J Clin Oncol. 2003 Jan 15;21(2):283-90
references.pmid: 12525520
references.citation: J Clin Pharm Ther. 2004 Apr;29(2):95-103
references.pmid: 15068398
references.citation: N Engl J Med. 2002 Feb 28;346(9):683-93
references.pmid: 11870247
references.citation: Oncologist. 2002;7(5):401-9
references.pmid: 12401902
references.citation: N Engl J Med. 1999 Nov 18;341(21):1565-71
references.pmid: 10564685
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073
references.citation: Tumour Biol. 2000 Nov-Dec;21(6):358-66
references.pmid: 11006576
references.citation: J Clin Oncol. 2001 Jul 1;19(13):3234-43
references.pmid: 11432891
references.citation: J Clin Oncol. 2003 Jan 1;21(1):60-5
references.pmid: 12506171
references.citation: N Engl J Med. 2001 Mar 15;344(11):783-92
references.pmid: 11248153
references.citation: J Clin Oncol. 1999 Sep;17(9):2639-48
references.pmid: 10561337
references.citation: J Clin Oncol. 2004 Apr 1;22(7):1180-7
references.pmid: 14981103
references.citation: J Clin Oncol. 2004 Aug 1;22(15):3126-32
references.pmid: 15284264
references.citation: Oncologist. 2004;9(4):357-60
references.pmid: 15266089
references.citation: Cancer Res. 1993 Oct 1;53(19):4550-4
references.pmid: 8402626
references.citation: Gynecol Oncol. 2003 Mar;88(3):263-5
references.pmid: 12648572
references.citation: Semin Radiat Oncol. 2003 Oct;13(4):454-68
references.pmid: 14586834
references.citation: Clin Cancer Res. 2001 May;7(5):1204-13
references.pmid: 11350885